FDA's AI tool for medical devices struggles with simple tasks
The tool — which is still in beta testing — is buggy, doesn't yet connect to the FDA's internal systems and has issues when it comes to uploading documents or allowing users to submit questions, the people say. It's also not currently connected to the internet and can't access new content, such as recently published studies or anything behind a paywall.
The artificial intelligence, dubbed internally CDRH-GPT, is intended to help staffers at the agency's Center for Devices and Radiological Health, a division responsible for ensuring the safety of devices implanted in the body as well as essential tools like X-rays and CT scanners.
The division was among those affected by the sweeping mass layoffs at the Department for Health and Human Services earlier this year. While many of the device reviewers were spared, the agency eliminated much of the backend support that enables them to issue approval decisions on time.
The work of reviewers includes sifting through large amounts of data from animal studies and clinical trials. Depending on the applicant, it can take months or even over a year — which an AI tool could feasibly help shorten.
Experts, however, are concerned that the FDA's push toward AI could outpace what the technology is actually ready for.
Since taking over the agency on April 1, Commissioner Dr. Marty Makary has pushed to integrate artificial intelligence across the FDA's divisions. How this move into AI could affect the safety and effectiveness of drugs or medical devices hasn't been determined.
Last month, Makary set a June 30 deadline for the AI rollout. On Monday, he said the agency was ahead of schedule.
But the two people familiar with CDRH-GPT say that it still needs significant work and that FDA staff were already concerned about meeting the June deadline, at least in its original form.
'I worry that they may be moving toward AI too quickly out of desperation, before it's ready to perform,' said Arthur Caplan, the head of the medical ethics division at NYU Langone Medical Center in New York City. He stressed that reviewing medical devices accurately is essential, since people's lives depend on it.
'It still needs human supplementation,' Caplan said. AI 'is really just not intelligent enough yet to really probe the applicant or challenge or interact.'
The FDA directs all media inquiries to the Department of Health and Human Services. A spokesperson for HHS did not respond to a request for comment.
On Monday, Makary announced that a separate AI tool, called Elsa, had been rolled out to all FDA employees. Elsa is now intended for basic tasks agency-wide, such as summarizing data from adverse event reports.
'The first reviewer who used this AI assistant tool actually said that the AI did in six minutes what it would normally take him two to three days to do,' Makary said in an interview last week. 'And we're hoping that those increased efficiencies help. So I think we've got a bright future.'
The reality inside the agency is quite different, the same two sources said.
While the concept is solid and a step in the right direction, they said, some staff feel it's being rushed and not yet ready for prime time.
'AI tools to help with certain tasks for reviewers and scientists seems reasonable given the potential utility of AI,' one of the people said. However, the person said they disagree with the 'aggressive roll out' and claims that it could reduce work 'by hours and days.'
To be sure, experts say, it's not uncommon for a company or government agency to launch a new product and then refine it through iterative updates over time.
Staff have worked hard to get Elsa up and running, the people said, but it still can't handle some core functions and needs more development before it can support the agency's complex regulatory work.
When staff tested the tool Monday with questions about FDA-approved products or other public information, it provided summaries that were either incorrect or only partially accurate, one of the people said.
It's unclear, the people said, whether CDRH-GPT will eventually be integrated into Elsa or remain a standalone system.
Richard Painter, a law professor at the University of Minnesota and a former government ethics lawyer, said there are also concerns about potential conflicts of interest. He wondered whether there is a protocol in place to prevent any government official — such as an FDA reviewer using the technology — from having financial ties with companies that could benefit from AI. While the technology has existed for years, he said, it's still a new venture for the FDA.
'We need to make sure that the people involved in these decisions do not have a financial interest in the artificial intelligence companies that would get the contracts,' Painter said. 'A conflict of interest can greatly compromise the integrity and the reputation of a federal agency.'
Some at the FDA don't see AI as a solution to their overwhelming workloads — they see it as a sign that they may eventually be replaced.
The FDA is 'already spread thin from the RIF [layoffs] and the steady loss of individuals while in a hiring freeze and no capacity to backfill,' one of the people said.
This article was originally published on NBCNews.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
FDA warning: Don't eat these potentially radioactive shrimp sold at Walmart
You might want to think twice about buying this brand of shrimp next time you're shopping at Walmart. The U.S. Food and Drug Administration issued a warning to consumers about eating, selling or serving select brands of Great Value frozen raw shrimp due to contamination with a radioactive isotope. U.S. Customs and Border Protection alerted the FDA about the radioactive isotope, Cesium-137, after it was found in shipping containers at four U.S. seaports, according to the FDA. Here's what you need to know about the products that are affected and whether a recall will be imminent. What contaminated shrimp is the FDA warning consumers about? The Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp in 2-pound bags distributed by Indonesia's BMS Foods tested positive for the contamination. The FDA is recommending a recall on certain BMS shrimp products even if they did not test positive. While a recall hasn't been conducted yet, the FDA is working with distributors and retailers 'to recommend' a recall. The following products are affected: Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: 3/15/2027 The products were sold in Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. What should people do if they have the contaminated raw shrimp? The FDA is advising people who might have raw, frozen shrimp in their freezers from Walmart that matches the descriptions to not cook or consume them. Instead, the agency is asking customers, distributors and retailers to throw the shrimp away. The FDA also says, 'If you suspect you have been exposed to elevated levels of cesium, talk to your healthcare provider.' Consuming food or water contaminated with Cs-137 in low doses over an extended period of time can create an elevated risk of cancer due to a breakdown in DNA in the body's living cells, according to the FDA. Our journalism needs your support. Please subscribe today to Katherine Rodriguez can be reached at krodriguez@ Have a tip? Tell us at Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
FDA Pushes Back Eylea HD Review; Regeneron Still Gains
This article first appeared on GuruFocus. Regeneron (NASDAQ:REGN) picked up gains Tuesday after announcing that the FDA pushed back decision timelines for two key reviews of its high-dose Eylea (aflibercept) injection. The new action dates fall in the fourth quarter of 2025, covering a prior-approval supplement for a prefilled syringe and a label expansion filing to treat macular edema after retinal vein occlusion (RVO). Warning! GuruFocus has detected 3 Warning Signs with REGN. The company is also seeking to expand Eylea HD's dosing schedule to every 4 weeks across approved uses a shift from the current 816 week regimen for patients with wet AMD and diabetic macular edema. The extension stems from additional information submitted after an FDA inspection at Catalent Indiana LLC, the third-party manufacturer recently acquired by Novo Nordisk (NVO). The FDA classified the new submission as a major amendment, automatically extending review timelines. Novo Nordisk provided a detailed response earlier this month in an effort to address the agency's concerns. For now, Eylea HD remains available via vial administration, but the delay tempers near-term expectations around label expansion and convenience upgrades. Still, investors seem encouraged, with shares moving higher on confidence the regulator will complete its review later this year. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
The Hill
2 hours ago
- The Hill
Walmart recalls frozen shrimp over potential radioactive contamination
Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia. The products could pose a 'potential health concern' for people exposed to low levels of Cesium-137 over time, FDA officials said. 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away,' FDA officials said in a statement. The risk from the recalled shrimp is 'quite low,' said Donald Schaffner, a food safety expert at Rutgers University. Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air. The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time. The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia. FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S. However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts. Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
